Aldeyra Therapeutics, Inc. (ALDX) Earnings History
Net Loss15 years of earnings data (2011–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Aldeyra Therapeutics, Inc. (ALDX) Earnings Overview
As of July 7, 2026, Aldeyra Therapeutics, Inc. (ALDX) reported trailing twelve-month net income of -$27M, reflecting +40.4% year-over-year growth. The company earned $-0.45 per diluted share over the past four quarters.
Looking at the long-term picture, ALDX's historical earnings data spans multiple years. The company achieved its highest annual net income of $13M in fiscal 2013.
Aldeyra Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including OCUL (-$290M net income, -513.2% margin), KALA (-$20M net income), HALO ($349M net income, 22.7% margin), ALDX has comparable earnings metrics. Compare ALDX vs OCUL →
ALDX Earnings vs Peers
Earnings metrics vs comparable public companies
ALDX Historical Earnings Data (2011–2025)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$34M | +39.4% | -$35M | $-0.56 | - | - |
| 2024 | -$56M | -48.8% | -$60M | $-0.94 | - | - |
| 2023 | -$38M | +39.5% | -$43M | $-0.64 | - | - |
| 2022 | -$62M | -7.4% | -$63M | $-1.06 | - | - |
| 2021 | -$58M | -53.8% | -$56M | $-1.07 | - | - |
| 2020 | -$38M | +38.3% | -$36M | $-1.11 | - | - |
| 2019 | -$61M | -56.4% | -$63M | $-2.24 | - | - |
| 2018 | -$39M | -74.1% | -$40M | $-1.79 | - | - |
| 2017 | -$22M | -19.5% | -$22M | $-1.40 | - | - |
| 2016 | -$19M | -54.7% | -$19M | $-1.65 | - | - |
| 2015 | -$12M | -133.1% | -$12M | $-1.40 | - | - |
| 2014 | -$5M | -139.7% | -$7M | $-1.35 | - | - |
| 2013 | $13M | +156.6% | -$4M | $2.72 | - | - |
| 2012 | -$23M | -870.4% | -$1M | $-19.22 | - | - |
| 2011 | -$2M | - | -$2M | $-0.50 | - | - |
Download Data
Export ALDX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ALDX — Frequently Asked Questions
Quick answers to the most common questions about buying ALDX stock.
What is ALDX earnings per share (EPS)?
ALDX trailing twelve-month (TTM) diluted EPS is $-0.45, reflecting +40.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.
What is Aldeyra Therapeutics, Inc.'s net income?
Aldeyra Therapeutics, Inc. (ALDX) trailing twelve-month net income is $-27M as of 2025. Earnings grew +40.4% year-over-year.
Is ALDX profitable?
ALDX is not currently profitable on a TTM basis, reporting a net loss of $-27M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ALDX's earnings growth rate?
ALDX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.
What are ALDX's profit margins?
Aldeyra Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -58.7%.
Is ALDX growing earnings?
Yes, ALDX earnings are accelerating — EPS growth of +40.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-27M. Earnings momentum is strengthening.
What was ALDX's best earnings year?
Aldeyra Therapeutics, Inc.'s highest annual net income on record is $13M, achieved in fiscal year 2013. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.
What were ALDX's earnings last quarter?
ALDX's most recent reported quarter was Q1 2026. Net income was $-3M with diluted EPS of $-0.06. For a full breakdown of all quarters, see the quarterly earnings table on this page.